Immune Design (IMDZ) Misses Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Immune Design (IMDZ) Misses Q2 EPS by 7c

Immune Design (IMDZ) Files $250M Common Stock Shelf

August 12, 2015 4:31 PM EDT

Immune Design (NASDAQ: IMDZ) filed a registration with the U.S. SEC to sell up to $250 million of its common stock.

... More

Immune Design (IMDZ), Genentech (RHHBY) Enter Collaboration to Evaluate CMB305, MPDL3280A Combo

August 12, 2015 8:04 AM EDT

Immune Design (NASDAQ: IMDZ) announced it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of Immune Design's CMB305 cancer immunotherapy product candidate combined with the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) in a... More